All In Biotech

Drug Trial Radar · NCT06031259

Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment

An Open-Label Extension for Subjects in Studies HGT-HIT-046 and SHP609-302 Evaluating Long-Term Safety of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Subjects With Hunter Syndrome and Cognitive Impairment

Last checked: Nov 20, 2026Latest source record: Nov 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

6

Actual

Start

Mar 5, 2024

Primary completion

Jan 1, 2029

Study completion Jan 1, 2029

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Sep 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 3 years, up to 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is an extension of two previous studies (HGT-HIT-046 \[NCT01506141\] and SHP609-302 \[NCT02412787\]). Participants must have completed one of the previous studies. The main aim of this study is to collect more information about the safety of the treatments, idursulfase-IT and elaprase, in children and adults with Hunter syndrome and cognitive impairment. Participants will receive the same treatment as in the previous studies.

Conditions

  • Hunter Syndrome

Interventions

  • Idursulfase-ITDrug

    Idursulfase-IT intrathecally via IDDD.

  • ElapraseDrug

    Elaprase IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs) by Type and SeverityTime frame: Up to approximately 4.8 years
  2. Number of Participants with AEs Related to Idursulfase-ITTime frame: Up to approximately 4.8 years
  3. Number of Participants with AEs Related to the IDDDTime frame: Up to approximately 4.8 years
  4. Number of Participants with AEs Related to Device Surgical ProcedureTime frame: Up to approximately 4.8 years
  5. Number of Participants with AEs Related to IT Administration ProcessTime frame: Up to approximately 4.8 years
  6. Number of Participants with AEs Related to IV Elaprase InfusionTime frame: Up to approximately 4.8 years

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • M.A.G.I.C. Clinic

    Calgary, Alberta, Canada

  • University of British Columbia

    Vancouver, British Columbia, Canada

  • Hospital for Sick Children

    Toronto, Ontario, Canada

  • Hopital Femme Mere Enfant

    Bron, Auvergne-Rhône-Alpes, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.